To reveal whether NCAPG affects the proliferation of HCC through PTEN and the PI3K-AKT pathway, we investigated whether the PI3K-AKT pathway inhibitor MK2206 could attenuate the proliferation of liver cancer. Here, AKT1 is linked to liver cancer.